Editorial: bezafibrate in the treatment of patients with primary biliary cholangitis-are we there yet? Authors' reply

Aliment Pharmacol Ther. 2022 Jan;55(2):249-250. doi: 10.1111/apt.16726.

Authors

Juan Antonio Sorda¹, Esteban González Ballerga¹, Fernando Javier Barreyro², Jorge Daruich¹

Affiliations

¹ Department of Gastroenterology and Hepatology, University Hospital "José de San Martín", Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina.
² Biotechnology Institute of Misiones (INBIOMIS), National University of Misiones, National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.

PMID: 34970761
DOI: 10.1111/apt.16726

No abstract available

Publication types

Editorial
Comment

MeSH terms

Bezafibrate / therapeutic use
Cholangitis* / chemically induced
Cholangitis* / drug therapy
Humans
Liver Cirrhosis, Biliary* / drug therapy
Ursodeoxycholic Acid

Substances

Ursodeoxycholic Acid
Bezafibrate